Welldoc is powering Lilly’s new digital health platform, designed to support individuals prescribed incretin therapies such as Zepbound® and Mounjaro®. The platform offers personalized support to help manage cardiometabolic conditions, including type 2 diabetes, obesity, and moderate-to-severe obstructive sleep apnea. It includes features such as medication reminders, dose tracking, health data logging, and customized digital coaching.

The collaboration combines Welldoc’s FDA-cleared, AI-driven digital health platform with Lilly’s commitment to innovation in therapeutics—a notable example of how pharmaceutical and digital health organizations are working together to deliver more intelligent, connected care experiences.

Last year, Welldoc’s Chief AI Officer, Anand Iyer, joined us on the FH24 main stage to share insights on responsibly integrating AI into regulated digital health solutions. You can watch the full session, “AI in Digital Health Pathways: Responsibly Integrating AI in Regulated Solutions,” here.

Date: June 4^th, 2025 | Source: www.welldoc.com

Join us and our global community of health innovators in Berlin on November 11-12, 2025.

Get your pass now!